Sequence variation in ACE, encoding angiotensin I converting enzyme, contributes to a large proportion of variability in plasma ACE levels, but the extent to which this impacts upon human disease is unresolved. Most efforts to associate ACE with other heritable traits have involved a single Alu insertion/deletion polymorphism, despite the probable existence of other functional sequences variants with effects that may not be consistently detectable by solely typing the Alu indel. Here, utilizing single nucleotide polymorphisms (SNPs) that differentiate major ACE clades in European populations, we demonstrate a number of significant phenotype associations across more than 4000 Swedish individuals.
Introduction
Common variants of ACE, encoding angiotensin I converting enzyme (ACE), contribute to a large proportion of variance in circulating plasma ACE levels, a relationship that represents one of the most compelling examples of a genetic effect upon a complex trait in human populations (1, 2) . Association of ACE has been claimed with numerous phenotypes, including myocardial infarction (MI), Alzheimer disease (AD), type II diabetes, and various quantitative traits related to these disorders (3) (4) (5) . Typically, these studies have focused on a single Alu insertion/deletion polymorphism in intron 16 of ACE and they have generally been conducted on relatively small populations. As a consequence, results have been inconsistent, leaving open the implicit question of whether or not altered ACE activity can mediate susceptibility to disease and/or variation in disease-related traits.
Studies on ACE and ACE plasma levels have provided strong evidence that several polymorphic sites contribute to the observed phenotypic variation (2, 6, 7) . These findings of allelic heterogeneity have been facilitated by exhaustive searches for DNA sequence variation across the gene and by haplotype
and cladistic analyses to demonstrate associations (8) (9) (10) . These analytical strategies have highlighted the importance of studying linkage disequilibrium (LD) structure within and around a locus that may harbor multiple variants that influence a trait of interest. In European populations, the ACE locus is marked by strong LD between polymorphic sites and consequently by a small number of common extant haplotypes. Limited haplotype diversity in the vicinity of ACE prohibits the fine-mapping of specific alleles that contribute to variability in the ACE trait (11, 12) . However, strong LD also implies a relatively simple allelic architecture, whereby common haplotypes can be discerned with a limited number of genetic markers and then used in association analyses (13, 14) . A simple cladistic structure with three major ancestral clades (A,B, and C) was proposed by Farrall et al. for populations of European ancestry (8) . Theoretical and practical aspects of clade-based modeling have been dealt with previously (15, 16) .
We have utilized the well-documented LD and haplotype structure of the ACE locus to guide the selection of markers that delineate the major ACE clades and used these in a multi-tiered association study. Our primary motivation has been that if allelic heterogeneity is present, the application of a simple clade model might be an appropriate step forward in attempting to replicate and clarify previously claimed associations of ACE variants with metabolic quantitative traits and discrete disease states, in particular MI and AD.
Results
The previously proposed genealogy of ACE entails three common ancestral clades (A, B, and C) whereby clade C was putatively formed by recombination between haplotypes of the A and B clades (8, 9) . Clade A has been shown to be associated with low plasma ACE activity, clade B with higher activity, and the C clade with intermediate levels (9, 14) . In effect, typing only two markers, one on either side of the recombination site, is sufficient to distinguish these three clades, at least in Europeans (9, 14) . We note that Soubrier et al. (14) selected three SNPs to distinguish the effects of four clades (which included a D clade). The D clade was observed to be quite rare however, and on this basis we considered it imprudent to attempt to delineate its independent effects in the present study.
Following efforts to define LD structure around the ACE locus (see methods), three SNPs were selected for genotyping in all studied clinical materials; one occurring in the 3' region of ACE (rs4343), and two that occur in the promoter (rs4291 and rs1800764). All markers were found to be in Hardy-Weinberg equilibrium. The selection of this particular 3' marker was based upon the robustness of its genotyping assay, since near-perfect LD makes numerous markers in this region equivalent (and thus redundant), including the Alu I/D polymorphism (17) . Two 5' markers were selected since LD is slightly weaker for this region. These markers have previously been shown to have local maximum effects upon ACE plasma levels, thus suggesting putative independent functional effects (2, 18).
For haplotype construction, combining the rs4343 marker with either of the two 5' SNPs (either rs4343 + rs4291 or rs4343 + rs1800764) creates haplotypic genotypes that reflect combinations of the major A, B, and C clades (14, 17) . For brevity, we refer to haplotypic genotypes throughout this study as cladetypes. For initial analyses using this strategy, cladetypes were constructed using the rs4343 + rs1800764 combination. Posterior probability estimates for individual phase calls using HAPLOTYPER were all in excess of 0.95. from these materials (19, 20) , the investigation was limited to 17 that are commonly examined in relation to cardiovascular disease (21, 22) (table 1) . We acknowledged that many of these would exhibit strong correlations, thus entailing some redundancy, but opted nonetheless to investigate each independently. For example, several measures of obesity were examined due to uncertainty about which most accurately predicts cardiovascular disease risk (23) . The intention was to perform a systematic evaluation of traits that would limit the number of tests in initial exploratory analyses, while at the same time providing sufficient power to detect associations if present. We have presumed that power will decrease as one moves away from primary biological effects (e.g. ACE plasma levels) to intermediate effects (e.g. metabolic traits) to disease risk, and as such justified the order of phenotype analysis in this study. These analyses were performed in three stages listed below.
Stage I
Cladetypes were tested against all quantitative traits listed in table 1 in men and women separately.
Results for these analyses are shown in table 2. We noted that with 34 tests (17 traits in both men and women), at least one nominal uncorrected P-value of 0.0015 would be required to declare formal significance from this preliminary phenotype screen (assuming a strict Bonferroni correction with α = 0.05). The number of individuals in the C/C clade category was small (a total of 18 individuals in this sample) and this group was therefore excluded from initial comparisons. Among the tested traits, the strongest evidence of association was obtained for fasting plasma glucose (FPG) levels in men (P = 0.000041). There was no evidence for an effect in women (P = 0.67). Additional traits which exhibited significant evidence of association include BMI (P = 0.012), HOMA (P = 0.0053), insulin levels (P = 0.011), WC (P = 0.0023), and WHR (P = 0.022), all evident exclusively in men (table 2) . At this stage we also tested the alternative model involving the rs4343+rs4291 combination and specifically examined the FPG trait. This produced a P-value of 0.0014 in the male sample. On the basis of the weaker evidence for this model, all further work was done using the rs4343+rs1800764 combination.
Stage II
Cladetype analyses were performed in men after stratification into infarct patients and controls, focusing on the six traits that exhibited evidence of association in stage I. This revealed significant effects upon the FPG trait in both groups (table 3) . However, for the other traits, significant effects were observed only in infarct patients (table 3 
Stage III
Individual markers were tested for association in male MI patients with the six traits that exhibited significance in stages I and II. The results for these analyses are shown in table 4. A trend was apparent, whereby the rs1800764 marker provided consistent and strong evidence of association, whereas the rs4343 variant exhibited relatively weak effects (table 4 ) . Again, adjusting the strongest finding (rs1800764 and theWC trait) for age and smoking improved the model fit (F 2,482 = 9.0, P = 0.0001). The proportion of total variance in WC explained in this model is 3.5% (contrast to the above 6.2% for the clade model). For comparison, variability at rs4343 (which is in nearly perfect LD with the Alu indel) explains only 1.6% of the variance in WC (specific data not shown).
Disease Associations
Cladetype distributions were compared in MI patients and controls and in an extended set of Swedish AD materials and controls previously described (17) . Our intention was to apply the models that had been used to detect quantitative trait associations to explore the possibility that ACE affects these diseases differentially as has been postulated in several previous studies (24) (25) (26) . The results of this analysis are presented in table 5. For MI, significant association was observed in the male sample where an enrichment of the AB cladetype was evident in the infarct group (P = 0.0077). Importantly however, inclusion of WC as a covariate completely eliminates the significance in this model (final model P = 0.39). This could indicate that the MI effect is secondary to obesity, but one caveat in this is that the number of individuals with obesity phenotypes is smaller than the total sample implying a reduction in sample size and thus power in this obesity adjusted model. For comparisons involving the AD sample, the AA cladetype was found to be enriched in cases (P = 0.0011). Effects were similar when analyzing men and women separately (see text of table 5), and thus only a combined sample is presented. Single marker genotypes were also tested for disease association in 3 x 2 contingency tables. In the male MI population, borderline significance was seen for rs4343 and rs1800764 (χ 2 P-values of 0.056 and 0.088, respectively). For the complete AD set compared with controls and for these same markers, significances were P = 0.055 and P = 0.30, respectively.
Clade frequencies across age-groups
Contingency tables were constructed for the comparison of cladetype distributions as a function of age.
To model these effects, the entire set of control samples (≈ 2200 individuals) was stratified into thirds defined by tertiles. The results of this analysis are shown in table 6. Similar findings were obtained for men and women analyzed separately (data not shown). As an alternative to this strategy, we also used ANOVA, treating age as a quantitative trait dependent upon genotype, which produced similar results (F 4,2218 = 3.80, P = 0.0044) (specific data for each genotype group not shown). Single marker tests examining rs4343 and rs1800764 in 3x3 contingency tables produced χ 2 P-values of 0.010 and 0.091, respectively.
Genomic contexts and potential regulatory effects of ACE variants
The genomic contexts of bi-allelic polymorphisms extending across ACE were analyzed for potential regulatory effects using RAVEN (see Materials and Methods). We initially examined all validated SNPs (those entries with population frequency data or with multiple independent submissions to dbSNP) spanning the ACE locus for occurrence in evolutionarily conserved regions. This preliminary sweep was done using the UCSC genome browser (http://genome.ucsc.edu/) examining conservation between human/mouse/rat/chimp/chicken sequences. Work to further prioritize markers was primarily guided by a previous study in which a small number of sites were shown to exhibit independent effects upon ACE plasma levels (2) . Of the markers chosen for closer analysis, 4 are located 5' upstream of ACE transcription start site, 4 in exons resulting in synonymous substitutions, and 2 in introns. These findings are summarized in table 7. We refer to the standard, longer isoform of ACE (RefSeq accession number NM_000789). The shorter isoform is observed mostly in testis mRNA libraries, but was reproducibly isolated from at least one other tissue sample (medulla, cDNA library NIH_MGC_119).
Among all variants examined in this analysis, the synonymous marker rs4362 located within the 5' end of exon 23 (of ACE isoform 1) was considered the most likely functional candidate. The first 42 nucleotides of that exon are perfectly conserved between human and mouse sequences, which is observed exceptionally rarely across such an evolutionary distance when the conservation of the protein coding information is the only selection constraint. This strongly suggests that the region serves some additional function, possibly involving the regulation of expression or splicing. The search for known transcription factor sites revealed high potential of the region for binding zinc finger class transcription factors, which are known to bind in clusters to some regulatory regions (27) . The program ESEfinder (http://exon.cshl.org/ ESE) (28) was used to test the different alleles of this site for potential effects on the binding of serine/arginine-rich splicing factors (SR proteins). The C allele at this site is associated with two adjacent high-scoring SRp55 motifs which both are disrupted by the T allele (high scores dropping from 3.83 to 2.28 and 3.22 to 0.67, respectively).
Of the four promoter SNPs, marker rs4292 was deemed to be the most likely to have a functional role.
This marker is flanked by sequence highly conserved between human and rodents. Putative transcription factor binding sites detected therein include a cluster of Gflp (zinc finger) binding sites. Thus, rs4292
has the potential to abolish binding to one of the Gflp sites. Of the two alternative alleles, the minor one (T) is present in mouse and rat.
Discussion
Knowledge of sequence polymorphism, LD structure, and extant haplotype diversity in ACE across world populations is among the most extensive to date (10) . This information has been used to establish the influence of variation in ACE upon circulating ACE plasma levels (1, 7, 12) , a relationship that The data we present substantiate the prospect that variants of ACE do have a number of detectable phenotypic effects that extend beyond and possibly as a result of the impact of these variants upon ACE activity itself. These appear primarily to reflect an influence upon glucose/energy metabolism and obesity. In support of this, an effect upon glucose levels has been observed previously (29) and similarly a relatively large study recently demonstrated the plausible involvement of ACE in obesity (30) . Given differences between A and B clades, whereby the former is related to low ACE activity, and the latter to high activity, the plausible biological mechanism behind these observations is that elevated ACE activity increases trait levels. This hypothesis is supported by recent findings that treatment with ACE inhibitors leads to a significant decrease in both plasma glucose and insulin levels in a mouse model (31) , but also by evidence that chronic ACE inhibition may decrease the risk of type II diabetes (32, 33) .
Thus, together with the genetic data we present, it would appear plausible that the modification of ACE activity could lead to altered glucose and insulin levels, and obesity, as has been suggested (31, 34) .
Associations with quantitative metabolic traits were observed exclusively in men, which may derive in part from the sample size being considerably larger than for women. However, other studies have also detected associations exclusively in men (35) (36) (37) (38) and gender specific effects, especially in relation to metabolic phenotypes, may be a major confounding factor in genetic analyses (39, 40) . Our strategy has been systematic and hierarchical, leaving women unexamined at later stages. Thus, we cannot exclude the possibility that weak effects exist in women that might only be detectable in stratified analyses or in larger populations. Of greater potential concern is the evidence that association was more pronounced in the infarct patients. While the observation that glucose levels are influenced by ACE alleles in both infarct patients and controls in an equivalent manner is reassuring, the explanation for the considerably stronger effects upon obesity measures in the infarct group however is at present unknown. We speculate that this may reflect causal pathways between ACE alleles and MI or may be due to interaction with medication following infarct events. Importantly, none of the MI patients have taken ACE
inhibitors. Changes in post-infarct diet or a unique genetic background common to infarct patients could also contribute to this observation.
One of the most interesting features of these data was the evidence that different cladetypes influence obesity/MI and AD (see table 5 ). In light of recent epidemiological evidence that obesity may be a risk factor for AD (41), this appeared paradoxical. We believe that an explanation to this can be found in the multitude of biochemical functions of ACE. In addition to its well-defined role in the conversion of angiotensin I (angI) to angiotensin II (angII) and catabolism of bradykinin (42, 43), ACE has recently been implicated in β-amyloid (Aβ) degradation, itself one of the principle pathogenic agents in AD (44).
Thus, in the presence of low ACE activity (either due to possession of clade A alleles or other causes), levels of angI and bradykinin could be chronically elevated and result in reduced body weight, while at the same time Aβ could accumulate to neurotoxic levels. A diagram of this putative relationship is shown in figure 1 . We acknowledge however that this model may be oversimplified and not reflect the true complexity of the biochemical systems that underlie the observed data. Nonetheless, the assumption of pleiotropic effects of ACE alleles is affirmed (25, 26) . Thus, with regard to AD in particular, alleles of both A and B clades could be contributing to disease, either directly via Aβ, or indirectly via obesity, confounding the detection of genetic association.
The relationships between AD and obesity/MI might also have relevance to the long-standing question of whether or not ACE exhibits longevity effects (25) . If different alleles of ACE can contribute to mortality (via obesity/MI and AD) then strategies for addressing longevity will be dependent upon both the strength of the effects upon those diseases and their prevalences. In the present study, significantly different cladetype frequencies were observed across age-groups. In comparing the MI and AD casecontrol data, clades associated with AD seem to be those diminishing with age, as opposed to those associated with obesity or MI. This loosely conforms to the data previously presented by Schächter et al. (25) , where the Alu deletion allele (which occurs on B and C clades) was enriched in centenarians, appearing paradoxical given the assumed association of this allele with MI (45).
The vast majority of studies on ACE have examined a single Alu indel polymorphism in intron 16 (10), although there are a few exceptions where more than one variant has been examined (17, 46 (2) , and lies in between two sites exhibiting the greatest independent effects upon the ACE plasma trait. Importantly, for the Alu indel there was no direct evidence in the available cDNA or EST sequences that the Alu insertion could actively change the expression level or structure of the transcript. This would be in line with the findings of Cox et al., (2) , suggesting that this particular variant may be inert. While speculative, we envision from these data a possible two-site model, whereby a single promoter (possibly rs4292) and a single intragenic site (possibly rs4362) might explain functional differences between the A, B, and C clades in Europeans. We reiterate that the LD relationships between these markers make typing of more than two sites unnecessary to differentiate clades, at least in the European populations for which data are available. Thus, among the markers we have tested rs4921, rs4292 and rs1800764 in the promoter are essentially equivalent and segregate together, as do rs4363, rs4362, rs4343, Alu indel, rs4331, and rs4309 (see also ref. 14) . In light of this and depending on the specific ancestries of the populations examined, studies that have already typed the Alu indel may be able to conveniently increase their resolution by simply including a promoter variant.
In summary, efforts to relate genetic variation to human disease continue at an unprecedented rate, despite concerns that the number and complexity of the underlying genetic factors may be intractable.
Confronted with this, it is important for disease gene mapping efforts that human populations actually maintain variants that differentially affect gene function and that the genetic architecture of a locus is reasonably well resolved (especially in the specific population being studied) before association strategies are attempted. We believe we have employed this knowledge gainfully to demonstrate significant effects of ACE alleles upon several human phenotypes, principally quantitative traits related to energy metabolism and obesity. We further show that the models employed to demonstrate effects upon obesity, also efficiently capture effects upon MI and AD, two diseases that have long been posited to be associated with ACE (45, 47). That genotypes associated with MI and AD appear to influence these diseases in an opposite fashion may derive from the different biological functions of ACE involving proteolytic substrate diversity. Substantial research remains to be performed in order to resolve the number and character of biologically relevant alleles of ACE along with functional studies that will provide insight to the mechanism and the role of ACE in disease.
Materials and Methods
Clinical Materials.
The principal clinical DNA materials employed in this study derive from individuals participating in the Stockholm Heart Epidemiology Program (SHEEP), a population based case-control study aimed at investigating the effects of various risk factors for MI in men and women (19) . The subjects were aged 
SNP selection and verification
We initially developed genotyping assays for 13 markers extending across ACE, which were tested in 93
Swedish control samples. These were (from 5' -3') rs1800764, rs4291, rs4303, rs4309, rs4314, rs4331, Alu I/D, rs4343, rs4348, rs4976, rs4362, rs4363, and rs4364. Markers rs4303, rs4314, rs4348, rs4976, and rs4364 were monomorphic in this sample. Oligonucleotide sequences for DASH assays and PCR reactions as well as LD structure have been reported on previously (17) . Three SNPs were selected (see results) to be genotyped in the entire sample in the present study (rs1800764, rs4291, and rs4343).
Details on all markers may be found in the dbSNP database (http://www.ncbi.nlm.nih.gov/SNP/) under their respective IDs. Surrounding 50bp sequences in each direction were examined for repeats and duplicated sequences using Repeat-Masker (http://repeatmasker.genome.washington.edu/cgibin/RepeatMasker/) and BLAST (http://www.ncbi.nlm.nih.gov/blast).
Genotyping
Genotyping of SNPs was performed using an induced fluorescence resonance energy transfer modification of dynamic allele specific hybridization [iFRET-DASH (51)]. All PCR reactions were run in 10-20µl volumes with 1.5mM MgCl 2 and using 5-20ng genomic DNA.
Computational detection of potential regulatory effect of sequence variation
Marker loci were analyzed for their putative effects on the binding specificity of transcription factors from the JASPAR database (52). We extracted human:mouse:rat alignments of the regions around the SNPs from the UCSC Genome Browser (53) and searched for potential regulatory variation using a nascent web-based tool named RAVEN (Lenhard et al., in preparation; write to Boris.Lenhard@cgb.ki.se for early access). RAVEN combines phylogenetic footprinting (54) with scanning of all sequence variants for transcription factor binding sites that may be differentially affected by the variation.
Statistical analysis
Deviation from Hardy-Weinberg equilibrium for genotypes at individual loci as well as differences in genotype and cladetype distributions between discrete groups were assessed using the Pearson χ 2 statistic. Deviation from normality for trait distributions was assessed using the Kolgomorov-Smirnov test. Correlations between traits were established using Spearman's rho statistic. Tests for association between genotypes and quantitative traits were performed using Kruskal-Wallis analysis of ranks or the Mann-Whitney U test for traits with non-normal distributions, or alternatively, ANOVA for normally distributed traits. For MI and AD, adjusted odds ratios were estimated using logistic regression. The above statistical analyses were performed using StatView version 5.0 (Abacus Concepts). Haplotype frequencies were estimated using the HAPLOTYPER program (55). LD between marker pairs within ACE was estimated using the r 2 metric (56). 
Legends to Figures Figure 1
Proposed biochemical functions of ACE in relation to MI, obesity and AD. As well as being involved in the degradation of Aβ in the brain, somatic ACE releases angII and inactivates bradykinin (43, 44).
Higher ACE activity and obesity are associated with clade B (57), whilst alleles in clade A are associated with lower ACE levels and AD (17) . Obesity and MI may be risk factors for the development of AD (41), however the mechanism is currently unknown. Tables   Table 1 Values are the mean ± SEM according to genotype for six selected traits in the male infarct sample. The number of individuals in each category is shown in parenthesis. Significance was assessed using ANOVA for normally distributed traits and Kruskal-Wallis analysis of ranks for non-normally distributed traits. a -H values for nonnormally distributed traits. For the strongest finding (WC for rs1800764) an additional model was fitted with smoking and age as covariates (F 2,482 = 9.0, P = 0.0001). Cladetype counts (frequencies) in cases and controls. Global χ 2 P-values (shown at bottom) were calculated in 5x2 tables. For each individual cladetype, odds ratios (OR; adjusted for age and smoking for MI and age and gender for AD) and associated 95% confidence intervals were estimated using logistic regression comparing all other cladetype groups combined. For AD, the AA cladetype comparison was significant and equivalent in both males and females (OR 1.6, 1.1-2.4, P = 0.018 and OR 1.5, 1.1-2.1, P = 0.022, respectively). For AD and the CB cladetype significance was only evident in females (OR 1.8, 1.1-2.9, P = 0.031 compared to OR 1.4, 0.7-2.7, P = 0.37 for males). 
